Reboxetine (or EDRONAX, PROLIFT®) is mainly prescribed to treat unipolar depression, panic disorder, and attention deficit hyperactivity disorder.
Class: Norepinephrine Reuptake Inhibitor (NRI)
FDA Approval: 1999; International Only (AU, IE, IL, NZ, ZA, UK, AR, BR, CL, VE)
Dosage Forms: 2 mg, 4 mg
Biological Half-life: 12-12.5 hours
Side Effects: Dizziness, dry mouth, constipation, agitation, anxiety, insomnia, urinary retention, sexual dysfunction, hypotension
Routes of Administration: Oral
Pregnancy Category: B1 (AU)